Pharma channel feed

Bris­tol My­er­s' Op­di­vo scores pri­or­i­ty re­view in com­mon blad­der can­cer, mark­ing lat­est win in PD-1 bat­tle with Keytru­da

5 years ago
FDA+

As­traZeneca's non-prof­it vac­cine is, for now, cost­ing them mon­ey

5 years ago
Coronavirus

More in­fo on drug re­view time­lines? HHS and FDA pull Trump HHS’ last-minute pledge

5 years ago
FDA+

Bob­bing on a sea of crises, blue­bird's Nick Leschly sees his pay cut in half as the biotech pre­pares to split

5 years ago
People

House com­mit­tee to grill Ab­b­Vie CEO next month on sup­press­ing Hu­mi­ra com­pe­ti­tion

5 years ago

Mer­ck, Roche and Bris­tol My­ers nab 4 of 6 pos­i­tive ODAC votes for ‘dan­gling’ ac­cel­er­at­ed ap­provals

5 years ago
R&D
FDA+

Ken Fra­zier ends his 29-year tenure at Mer­ck on a sour note, re­veal­ing a dip in sales in his fi­nal earn­ings call

5 years ago

Star­ing at a down quar­ter for Op­di­vo, Bris­tol My­ers keeps its eyes on price com­pe­ti­tion po­ten­tial in packed PD-1 mar­ket

5 years ago

Sanofi is ex­pand­ing at light speed abroad, but it's leav­ing be­hind a Penn­syl­va­nia plant and its 75 em­ploy­ees

5 years ago
Manufacturing

ODAC votes to keep Keytru­da and Tecen­triq ac­cel­er­at­ed ap­provals in blad­der can­cer

5 years ago
FDA+

The pres­sure builds for Em­ma Walm­s­ley as Glax­o­SmithK­line miss­es Q1 pro­jec­tion, drops more can­cer drugs

5 years ago

Opin­ion: Mean­ing­ful drug pric­ing re­forms are head­ed nowhere fast

5 years ago
FDA+
Opinion

Sanofi re­ports sales growth amid Dupix­en­t's Chi­na launch, but re­veals PDU­FA de­lay in Pompe dis­ease pro­gram

5 years ago

Eli Lil­ly shares take a hit as com­pa­ny low­ers full-year fore­cast

5 years ago

Pa­tient deaths force Astel­las to write off $540M of their $3B gene ther­a­py buy­out as time­line grows and tar­get group shrinks

5 years ago

Bio­gen's Michel Vounatsos takes home $18.7M in pay as the com­pa­ny bat­tles to take ad­u­canum­ab to mar­ket

5 years ago
People

Bio­gen re­vers­es course on com­pas­sion­ate use for ALS drug tofersen with plans to open pro­gram in Ju­ly

5 years ago
Cell/Gene Tx

Re­gen­eron's Len Schleifer, George Yan­copou­los start their am­bi­tious 5-year plan, earn­ing a front-loaded $270M com­bined

5 years ago
People

Biden signs two bills to clar­i­fy new chem­i­cal en­ti­ties, ed­u­cate on biosim­i­lars

5 years ago
FDA+

How the SCO­TUS de­ci­sion to gut the FTC could help bio­phar­ma com­pa­nies

5 years ago
FDA+

With 7 PD-(L)1s on the mar­ket, price com­pe­ti­tion has­n't been a fac­tor. Will Re­gen­eron be the first to ask for less?

5 years ago

Glax­o­SmithK­line hus­tles the 7th PD-1 past the fin­ish line with Jem­per­li. But how big will up­take be?

5 years ago
FDA+

Law pro­fes­sors call for FDA to dis­close all safe­ty and ef­fi­ca­cy da­ta for drugs

5 years ago
FDA+

Roche sees a slight dip in Q1 as biosim­i­lars keep bit­ing in­to block­buster on­col­o­gy tri­o's sales

5 years ago
Coronavirus
First page Previous page 245246247248249250251 Next page Last page
A service from the Financial Times